# Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

> **NCT02428218** · PHASE3 · WITHDRAWN · sponsor: **Biogen**

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis
- Relapsing Forms of Multiple Sclerosis

## Interventions

- **DRUG:** dimethyl fumarate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02428218
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-05
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Feasibility
- **Last updated:** 2016-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02428218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02428218, "Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02428218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*